TTF-1 expression stratifies chemoimmunotherapy benefits in PD-L1-negative lung adenocarcinoma: a real-world biomarker validation.

J Thorac Dis · 2025 · PMC12340273 · PMID 40809216

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

borderline significanceP=0.054so close (0.05 < p ≤ 0.1)

For OS, immunotherapy-containing regimen (aHR =0.48, 95% CI: 0.25–0.90; P=0.02) and ECOG-PS score (aHR =0.34, 95% CI: 0.16–0.70; P=0.004) retained prognostic significance, while chemotherapy backbone demonstrated borderline significance (aHR =0.51, 95% CI: 0.26–1.01; P=0.054).

also in 4,352 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.